Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-oxo-4h-chromene-2-carboxylic Acid (2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl)-phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)amide
2. Hm-30181
3. Hm30181
1. 849675-66-7
2. Hm-30181
3. Hm30181
4. Hm-30181-a
5. Pgp Inhibitor Hm30181ak
6. Encequidar [usan]
7. Hm30181ak
8. K4i4i996o4
9. 4-oxo-4h-chromene-2-carboxylic Acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl)-phenyl-2h-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide
10. Hm30181a
11. Hm-30181a
12. N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide
13. Unii-k4i4i996o4
14. 4h-1-benzopyran-2-carboxamide, N-(2-(2-(4-(2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-
15. 4h-1-benzopyran-2-carboxamide, N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl]phenyl]-2h-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-
16. N-(2-(2-(4-(2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-1-benzopyran-2-carboxamide
17. N-[2-[2-[4-[2-(3,4-dihydro-6,7-dimethoxy-2(1h)-isoquinolinyl)ethyl]phenyl]-2h-tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxo-4h-1-benzopyran-2-carboxamide
18. V5q
19. Encequidar [inn]
20. Encequidar (usan/inn)
21. Hm-30181 Free Base
22. Encequidar (hm30181)
23. Encequidar [who-dd]
24. Chembl4594298
25. Schembl13822558
26. Ex-a3429a
27. Dtxsid501100387
28. Bcp25240
29. Zib67566
30. Bdbm50567579
31. Hm 30181a
32. Mfcd25976625
33. S3431
34. Who 10861
35. Zinc68014383
36. Cs-6194
37. Db14070
38. Sb18921
39. Ac-36564
40. As-35283
41. Hy-13646
42. P-glycoprotein Inhibitor Hm30181ak
43. D11782
44. A857803
45. Q27281950
46. 4-oxo-4h-chromen-2-carboxylic Acid [2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-1h-isoquinolin-2-yl)-ethyl]-phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxy-phenyl]-amide
47. N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1h)-yl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-chromene-2-carboxamide
48. N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1h)-yl)ethyl)phenyl)-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl)-4-oxo-4h-chromene-2-carboxamide
Molecular Weight | 688.7 g/mol |
---|---|
Molecular Formula | C38H36N6O7 |
XLogP3 | 5.8 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 11 |
Exact Mass | 688.26454751 g/mol |
Monoisotopic Mass | 688.26454751 g/mol |
Topological Polar Surface Area | 139 Ų |
Heavy Atom Count | 51 |
Formal Charge | 0 |
Complexity | 1220 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of breast cancer , Treatment of soft tissue sarcoma
ABOUT THIS PAGE
43
PharmaCompass offers a list of Encequidar API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Encequidar manufacturer or Encequidar supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Encequidar manufacturer or Encequidar supplier.
PharmaCompass also assists you with knowing the Encequidar API Price utilized in the formulation of products. Encequidar API Price is not always fixed or binding as the Encequidar Price is obtained through a variety of data sources. The Encequidar Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Encequidar manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Encequidar, including repackagers and relabelers. The FDA regulates Encequidar manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Encequidar API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Encequidar supplier is an individual or a company that provides Encequidar active pharmaceutical ingredient (API) or Encequidar finished formulations upon request. The Encequidar suppliers may include Encequidar API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Encequidar as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Encequidar API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Encequidar as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Encequidar and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Encequidar NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Encequidar suppliers with NDC on PharmaCompass.
Encequidar Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Encequidar GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Encequidar GMP manufacturer or Encequidar GMP API supplier for your needs.
A Encequidar CoA (Certificate of Analysis) is a formal document that attests to Encequidar's compliance with Encequidar specifications and serves as a tool for batch-level quality control.
Encequidar CoA mostly includes findings from lab analyses of a specific batch. For each Encequidar CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Encequidar may be tested according to a variety of international standards, such as European Pharmacopoeia (Encequidar EP), Encequidar JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Encequidar USP).